Table IV.
Comparisons of CL between non-compartmental analysis and mPBPK model fitting
| Non-compartmental analysis | mPBPK | Comparison | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Compound | Mouse | Rat | Monkey | Human | Equation | Prediction CLhuman |
Equation | Prediction CLhuman |
Ratio of Prediction
human CL |
|
| |||||||||
| CL(×l0−4 L/h/kg) | (×10−4 L/h) | (×l0−4 L/h/kg) | (×10−4 L/h) | (×l0−4 L/h/kg) | CLNCA human/ CLmPBPK human |
||||
| Dacetuzumab | 4.58-7.05 | 4.61-4.58 | 5.17 | NA | CL=4.87×BW0.975 | 4.38 | CL=2.81×BW0.820 | 1.31 | 3.34 |
| Rituximab | 5.16-18.2 | 3.17-3.43 | NA | 44.8-49.2 | CL=11.5×BW1.24 | 31.8 | CL=3.02×BW0.888 | 1.87 | 17.0 |
| RSHZ19 | 2.49 | 3.96 | 1.43 | 1.19-1.35 | CL=2.06×BW0.886 | 1.26 | CL=1.64×BW0.867 | 0.92 | 1.36 |
| Bevacizumab | 72.2 | NA | NA | 1.40-1.80 | CL=11.5×BW0.532 | 1.57 | CL=4.07×BW0.762 | 1.48 | 1.06 |
| Trebananib | 7.04-7.63 | 17.4-20 | NA | 1.16-12.1 | CL=5.72×BW0.783 | 2.28 | CL=8.90×BW1.02 | 9.68 | 0.24 |
| Belimumab | NA | NA | 2.48-2.77 | 2.44-2.72 | CL=2.58×BW1.00 | 2.58 | CL=2.32×BW1.03 | 2.63 | 0.99 |
| AB-01 | 7.65 | 17.3 | 9.51-11.3 | NA | CL=11.1×BW1.02 | 12.1 | CL=8.08×BW0.893 | 5.13 | 2.35 |
| Erlizumab | 6.39 | 2.39-3.52 | 2.32-2.48 | 1.17 | CL=2.64×BW0.821 | 1.23 | CL=2.61×BW0.844 | 1.35 | 0.91 |
| Canakinumab | 2.04 | NA | 1.56 | 1.01 | CL=1.54×BW0.918 | 1.09 | CL=1.69×BW0.885 | 1.03 | 1.05 |
| SB249417 | NA | NA | 4.72-7.83 | 21.4-27.2 | CL=3.22×BW1.46 | 22.7 | CL=4.86×BW1.27 | 15.3 | 1.48 |
| Rilotumumab | NA | NA | 4.26-6.56 | 1.23-1.94 | CL=9.48×BW0.563 | 1.48 | CL=4.71×BW0.695 | 1.29 | 1.14 |
| AB-02 | NA | 28.1 | 44.1-51.0 | NA | CL=37.7×BW1.18 | 80.9 | CL=23.4×BW0.929 | 17.3 | 4.67 |
NA: not applicable